REG - OptiBiotix Health - WellBiome® clinical trial on surgical outcomes

OptiBiotix HealthAnnouncement

24/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260224:nRSX0691Ua&default-theme=true

RNS Number : 0691U  OptiBiotix Health PLC  24 February 2026

OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

 

 Clinical trial to evaluate the effect of WellBiome® on surgical outcomes
and NHS cost savings

 

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business
developing products which reduce hunger and food cravings, enhance the gut
microbiome, and sweet fibres as healthy sugar substitutes announces the
commencement of a clinical study with Hull University Teaching Hospital NHS
Trust to determine the effect of taking WellBiome on cardiac surgery outcomes
and potential NHS cost savings.

A number of studies (Ardema 2019, Xia 2021) have suggested a decrease in
microbial diversity and abundance post-surgery may increase hospital stays and
that prebiotics like WellBiome, which increase microbial diversity and
abundance and have systemic anti-inflammatory effects, may improve surgical
outcomes.

This double blind, placebo-controlled study of up to 60 patients is designed
to evaluate the effect of six-week pre-operative supplementation on time spent
in intensive care, length of hospital stay, and the incidence of
post-operative complications. The study includes a cost savings analysis to
identify any potential cost savings to the NHS and inform the future use of
prebiotics like WellBiome in improving health outcomes and cost savings.

WellBiome is a patented mineral-enriched prebiotic fibre complex developed in
collaboration with leading UK Universities to enhance gut microbiome diversity
greater than single prebiotic fibres alone.  WellBiome has a number of
European and USA on pack health claims including: -

·    Nourishes beneficial bacteria throughout the entire gut to improve
gut health

·    Contributes to improved bone health by aiding the absorption of
essential minerals

·    Contributes to normal muscle function, including heart muscle

·    Supports normal brain health function and memory

·    Contributes to normal psychological function

·    Supports cardiovascular health

·    Contributes to a reduction of tiredness and fatigue

Gut health is a growing health trend around the world with more than 80
percent of consumers in China, the United Kingdom, and the United States
considering gut health to be important, and over 50 percent anticipating
making it a higher priority in the next two to three years The top wellness
trends in 2024 | McKinsey
(https://www.mckinsey.com/industries/consumer-packaged-goods/our-insights/the-trends-defining-the-1-point-8-trillion-dollar-global-wellness-market-in-2024)
.  WellBiome was developed to meet this need and can be purchased from

www.optibiotix.online (http://www.optibiotix.online)   with a 30% discount
using the OPTI30 discount code.

 

 Stephen O'Hara, CEO of OptiBiotix, commented:

"Prebiotics like WellBiome are a growing trend for products which improve gut,
immune, and general health. More recently the systemic anti-inflammatory
effect of prebiotics has been suggested to improve post-surgical outcomes.
This NHS study by Hull University Hospitals Trust has been designed to
evaluate the potential of taking WellBiome as a preoperative supplement on
cardiac surgery patients on the length of time patients spend in ICU, length
of hospital stay, the impact on post operative complications, and potential
NHS cost savings. If successful it could lead to WellBiome becoming the
standard of care for NHS patients undergoing surgery".

This announcement contains information which, prior to its disclosure, was
considered inside information for the purposes of the UK Market Abuse
Regulation and the Directors of the Company are responsible for the release of
this announcement.

Engage with the OptiBiotix management team directly by asking questions,
watching video summaries and seeing what other shareholders have to say by
subscribing to the new website to get regular
updates:  https://optibiotix.com/auth/signup
(https://optibiotix.com/auth/signup)

View the full announcement and submit questions to management via our
website:  https://optibiotix.com/link/PbLd4e
(https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Foptibiotix.com%2Flink%2FPbLd4e&data=05%7C02%7Cspohara%40optibiotix.com%7C83c989d4f4694a657ac408de72e836ab%7Cfd9d39470fcc410da8d30ce1bec67dce%7C1%7C0%7C639074538836219445%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=o6kLLSnuv%2Fwrbc2Rvt368YWwgzzXTvD21Mn%2BK4VIihc%3D&reserved=0)

 

 

 For further information, please contact: OptiBiotix Health plc      www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD and Broker)                     Tel: 020 7213 0880
 Liam Murray / Ludovico Lazzaretti / James Western

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has
developed a range of technologies and commercialised products which modulate
the human microbiome to help prevent and manage human disease.  Since the
Group's inception it has created a wide range of microbiome-based ingredients
and products including prebiotic products like SlimBiome®, WellBiome®,
SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc
(OPTI) business, but also skincare through its holdings in SkinBioTherapeutics
PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies
create a diverse portfolio technologies and products in an emerging area of
healthcare that is of growing interest in consumer markets throughout the
world.

 

Caution regarding forward looking statements

 

Certain statements in this announcement, are, or may be deemed to be,
forward-looking statements. Forward-looking statements are identified by
their use of terms and phrases such as ''believe'', ''could'', "should"
''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'',
"expect", ''will'' or the negative of those, variations or comparable
expressions, including references to assumptions.  These forward-looking
statements are not based on historical facts but rather on the Directors'
current expectations and assumptions regarding the Company's future growth,
results of operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof), competitive
advantages, business prospects and opportunities. Such forward-looking
statements reflect the Directors' current beliefs and assumptions and are
based on information currently available to the Directors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSEIFWDEMSESE



            Copyright 2019 Regulatory News Service, all rights reserved